Kiora Pharmaceuticals Inc financial data

Symbol
KPRX on Nasdaq, KPHMW on OTC
Industry
Pharmaceutical Preparations
Location
332 Encinitas Boulevard, Suite 102, Encinitas, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
EYEGATE PHARMACEUTICALS INC (to 11/4/2021)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.21K % +288%
Debt-to-equity 30.1 % -52.9%
Return On Assets 16.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3M shares -61%
Common Stock, Shares, Outstanding 3M shares -61%
Entity Public Float 4.76M USD -22.1%
Common Stock, Value, Issued 268K USD +248%
Weighted Average Number of Shares Outstanding, Basic 4.21M shares +434%
Weighted Average Number of Shares Outstanding, Diluted 4.21M shares +434%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 4.83M USD +28.5%
General and Administrative Expense 5.1M USD -22.3%
Operating Income (Loss) 4.96M USD +39.1%
Nonoperating Income (Expense) 684K USD +177%
Net Income (Loss) Attributable to Parent 5.55M USD +40.8%
Earnings Per Share, Basic 11.9 USD/shares +88.9%
Earnings Per Share, Diluted 11.8 USD/shares +88.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.64M USD +4.38%
Accounts Receivable, after Allowance for Credit Loss, Current 1.78M USD
Assets, Current 31.7M USD +353%
Property, Plant and Equipment, Net 62.6K USD +62.1%
Operating Lease, Right-of-Use Asset 72.6K USD +288%
Intangible Assets, Net (Excluding Goodwill) 6.69M USD -24.2%
Goodwill 0 USD
Other Assets, Noncurrent 29.9K USD -6.7%
Assets 38.5M USD +142%
Accounts Payable, Current 660K USD +427%
Employee-related Liabilities, Current 1.03M USD +24.4%
Accrued Liabilities, Current 1.71M USD +17.3%
Liabilities, Current 3.53M USD +67.9%
Deferred Income Tax Liabilities, Net 779K USD +13.1%
Operating Lease, Liability, Noncurrent 39.2K USD
Liabilities 8.48M USD +8.81%
Accumulated Other Comprehensive Income (Loss), Net of Tax -75.2K USD +71.7%
Retained Earnings (Accumulated Deficit) -139M USD +3.84%
Stockholders' Equity Attributable to Parent 30M USD +271%
Liabilities and Equity 38.5M USD +142%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 13.6M USD
Net Cash Provided by (Used in) Financing Activities 15.2M USD +2871%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 150M shares +200%
Common Stock, Shares, Issued 3M shares -61%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 28.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.64M USD +4.39%
Deferred Tax Assets, Valuation Allowance 33M USD +11.6%
Deferred Tax Assets, Gross 34.5M USD +9.8%
Operating Lease, Liability 72.6K USD
Lessee, Operating Lease, Liability, to be Paid 82K USD +338%
Property, Plant and Equipment, Gross 14.4K USD -91.7%
Operating Lease, Liability, Current 33.4K USD +78.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 27.8K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.32K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.6K USD
Deferred Tax Assets, Operating Loss Carryforwards 26M USD +13.9%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.5K USD
Operating Lease, Payments 55.8K USD +0.07%
Additional Paid in Capital 169M USD +10.5%
Depreciation, Depletion and Amortization 4.87K USD -51.7%
Deferred Tax Assets, Net of Valuation Allowance 1.52M USD -18.8%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%